Kaitlynn Moser
Research Subjects
Research Interests
Kaitlynn Moser has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
D. Wagenbach
Institut für Umweltphysik, Universität Heidelberg, Im Neuenheimer Feld 366, 6900 Heidelberg, Federal Republic of Germany
1 shared publication- Daniela Geba
Ascenian Consulting and Market Research
1 shared publication K.O Münnich
Institut für Umweltphysik, Universität Heidelberg, Im Neuenheimer Feld 366, 6900 Heidelberg, Federal Republic of Germany
1 shared publication- Klaus Lindpaintner
InterVenn Biosciences
1 shared publication Michelle Soto
Olson Research Group
1 shared publicationPaul Allen
Olson Research Group
1 shared publication
Latest Publications
- Open Access
Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors
Background Immune checkpoint inhibitors (ICIs) are a valuable treatment option for patients with malignant tumors, but only selected patients respond to ICIs. Available biomarkers are of limited use in guiding ICI therapy. Objective To examine clinicians’ perspective on the use of ICIs and biomarkers for treatment of malignant tumors and to identify unmet needs related to their use. Methods We conducted in-depth telephone interviews of eight oncologists, and 100 oncologists completed online surveys. Results Oncologists have a positive attitude toward use of ICIs, and 98% of them prescribe them in all approved indications. Clinicians report that only about half of the patients with solid tumors responded to treatment, overestimated the response rate to ICIs across most types of tumors they treat compared with data in the literature. They ranked the lack of reliability of biomarkers to guide treatment (rating of 4.4 out of 7) as the top challenge with use of ICIs, followed by lack of overall efficacy and toxicity or occurrence of immune-related adverse events. The biomarkers most often used by survey participants were: a comprehensive panel including driver mutations and tumor mutational burden(69% of respondents), programmed cell death ligand-1 (PD-L1) expression (62%), and microsatellite instability (MSI) (56%). Oncologists indicated that they ordered biomarkers for each type of cancer according to their perceived usefulness of each biomarker in predicting the outcomes for ICI therapy, being more likely to use those perceived as useful or very useful. Conclusion Clinicians indicate that more reliable therapy-response prediction biomarkers would have a great impact on treatment decisions for patients with solid tumors, reducing unnecessary treatments, side effects, and health care expenditures.
Open AccessClinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors
Background Immune checkpoint inhibitors (ICIs) are a valuable treatment option for patients with malignant tumors, but only selected patients respond to ICIs. Available biomarkers are of limited use in guiding ICI therapy. Objective To examine clinicians’ perspective on the use of ICIs and biomarkers for treatment of malignant tumors and to identify unmet needs related to their use. Methods We conducted in-depth telephone interviews of eight oncologists, and 100 oncologists completed online surveys. Results Oncologists have a positive attitude toward use of ICIs, and 98% of them prescribe them in all approved indications. Clinicians report that only about half of the patients with solid tumors responded to treatment, overestimated the response rate to ICIs across most types of tumors they treat compared with data in the literature. They ranked the lack of reliability of biomarkers to guide treatment (rating of 4.4 out of 7) as the top challenge with use of ICIs, followed by lack of overall efficacy and toxicity or occurrence of immune-related adverse events. The biomarkers most often used by survey participants were: a comprehensive panel including driver mutations and tumor mutational burden(69% of respondents), programmed cell death ligand-1 (PD-L1) expression (62%), and microsatellite instability (MSI) (56%). Oncologists indicated that they ordered biomarkers for each type of cancer according to their perceived usefulness of each biomarker in predicting the outcomes for ICI therapy, being more likely to use those perceived as useful or very useful. Conclusion Clinicians indicate that more reliable therapy-response prediction biomarkers would have a great impact on treatment decisions for patients with solid tumors, reducing unnecessary treatments, side effects, and health care expenditures.
- Open Access
- 1 January 1990
- Published by International Glaciological Society in Annals of Glaciology
- Vol. 14, 349
Nitrate In Coastal Antarctic Shallow Firn Cores: Comparison Of Seasonal Pattern and Of Total Flux
With the intention of contributing to a better understanding of snow depth profiles used in reconstructing the southern hemisphere nitrate background we have measured C1−, , and in firn cores from two coastal Antarctic locations (GvN = Ekströmisen 70°S, 8°W, and Filchner = Filchner-Ronne Ice Shelf 79°S, 57°W). The depth resolution chosen is 2 cm per sample (i.e. 36 and 14 samples per year, respectively). The isotopie composition of the firn cores was concurrently measured, with equally high resolution (deuterium and 18O data, W. Graf, private communication). The GvN core yields an average accumulation rate of 35 cm H2O per year during the period 1979–86, while the Filchner core gives 14 cm H2O per year during the period 1955-80. The net snow accumulation being relatively high allows precise determination of the year to year boundaries, as well as the relative contribution of individual seasons to the total net accumulation. This was achieved by combining the stable isotope data with the chemical tracers nss-sulfate (high concentration in summer) and sea salt (high C1− in autumn and winter). For the two individual locations this procedure allowed assessment of the glacial nitrate concentration seasonality as well as comparing the yearly nitrate deposition. The Filchner location shows a distinct seasonality with maximum concentrations in summer. For nearly half of the years covered we also find higher concentrations in winter. This higher nitrate in winter is always accompanied by high sea salt concentrations. We suggest therefore a mechanism making sea salt aerosol an additional deposition pathway for nitrate in winter. This means that we are not able to link the enhanced winter nitrate deposition to stratospheric denitrification directly. The GvN core does not show significant seasonality. This is presumably due to frequent snow drift events preventing signal conservation. Although the individual accumulation rates differ by a factor of 2.5 the yearly nitrate deposition is in the same range (4-11 kg (km-2 a-1) at both sites. This is caused by the different seasonal modulation of the net snow accumulation. At GvN low nitrate autumn precipitation prevails and keeps the yearly nitrate level constantly low (18-22 ppb). At Filchner, however, a high contribution of summer snow brings the yearly concentration average up to about 30–70 pbb.
- 1 January 1990
- Published by International Glaciological Society in Annals of Glaciology
- Vol. 14, 349
Open AccessNitrate In Coastal Antarctic Shallow Firn Cores: Comparison Of Seasonal Pattern and Of Total Flux
With the intention of contributing to a better understanding of snow depth profiles used in reconstructing the southern hemisphere nitrate background we have measured C1−, , and in firn cores from two coastal Antarctic locations (GvN = Ekströmisen 70°S, 8°W, and Filchner = Filchner-Ronne Ice Shelf 79°S, 57°W). The depth resolution chosen is 2 cm per sample (i.e. 36 and 14 samples per year, respectively). The isotopie composition of the firn cores was concurrently measured, with equally high resolution (deuterium and 18O data, W. Graf, private communication). The GvN core yields an average accumulation rate of 35 cm H2O per year during the period 1979–86, while the Filchner core gives 14 cm H2O per year during the period 1955-80. The net snow accumulation being relatively high allows precise determination of the year to year boundaries, as well as the relative contribution of individual seasons to the total net accumulation. This was achieved by combining the stable isotope data with the chemical tracers nss-sulfate (high concentration in summer) and sea salt (high C1− in autumn and winter). For the two individual locations this procedure allowed assessment of the glacial nitrate concentration seasonality as well as comparing the yearly nitrate deposition. The Filchner location shows a distinct seasonality with maximum concentrations in summer. For nearly half of the years covered we also find higher concentrations in winter. This higher nitrate in winter is always accompanied by high sea salt concentrations. We suggest therefore a mechanism making sea salt aerosol an additional deposition pathway for nitrate in winter. This means that we are not able to link the enhanced winter nitrate deposition to stratospheric denitrification directly. The GvN core does not show significant seasonality. This is presumably due to frequent snow drift events preventing signal conservation. Although the individual accumulation rates differ by a factor of 2.5 the yearly nitrate deposition is in the same range (4-11 kg (km-2 a-1) at both sites. This is caused by the different seasonal modulation of the net snow accumulation. At GvN low nitrate autumn precipitation prevails and keeps the yearly nitrate level constantly low (18-22 ppb). At Filchner, however, a high contribution of summer snow brings the yearly concentration average up to about 30–70 pbb.